In terms of precision medicine, the clusters with minimal methylation changes exhibited fewer opportunities for targeted therapy (IDH1/2 mutation 0%, FGFR2 fusion 0%, BRCA1/2 mutation 6%, ERBB2 amplification 0%, BRAF mutation 0%), but a hot and inflamed tumor immune microenvironment (TIME), indicating favorable benefit from immunotherapy [32–41]. The gene discussed is BRCA1; the disease is neoplasm.